← Back to Search

Steroid Occipital Nerve Block for Headache

Phase 4
Recruiting
Led By Carrie Robertson, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 week, 2 weeks, 4 weeks
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial

Summary

This trial will look at if adding a steroid to occipital nerve block improves headaches.

Who is the study for?
This trial is for individuals who can consent, have been stable on headache prevention meds for at least a month, and suffer from headaches like occipital neuralgia or migraines. It's not for pregnant people, those with allergies to the drugs used, infections at the injection site, certain head or neck issues, or recent nerve blocks.
What is being tested?
The study tests if adding dexamethasone (a steroid) to an occipital nerve block helps more than just using local anesthetics (bupivacaine and lidocaine) with saline in treating headaches. Participants will receive these treatments directly around the nerves that might cause their pain.
What are the potential side effects?
Possible side effects include reactions at the injection site such as pain or infection, allergic reactions to any of the medications used (bupivacaine, lidocaine, dexamethasone), and potential short-term increases in blood sugar levels due to steroids.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 week, 2 weeks, 4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 week, 2 weeks, 4 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Headache days 1 week following treatment
Headache days 2 weeks following treatment
Headache days 4 weeks following treatment
Secondary study objectives
Acute medication use
Headache Severity
Location of headache
+1 more

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Anesthetic with dexamethasone groupExperimental Treatment4 Interventions
Subjects scheduled for bilateral greater/lesser occipital nerve blocks as part of clinical care will receive standard of care medication, including lidocaine and bupivacaine and dexamethasone.
Group II: Anesthetic without steroid groupActive Control4 Interventions
Subjects scheduled for bilateral greater/lesser occipital nerve blocks as part of clinical care will receive standard of care medication, including lidocaine and bupivacaine and normal saline.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bupivacaine
2013
Completed Phase 4
~1530
Lidocaine
2011
Completed Phase 4
~1370
Dexamethasone
2007
Completed Phase 4
~2650

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,362 Previous Clinical Trials
3,065,886 Total Patients Enrolled
17 Trials studying Headache
880 Patients Enrolled for Headache
Carrie Robertson, MDPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
10 Total Patients Enrolled
1 Trials studying Headache
10 Patients Enrolled for Headache

Media Library

Greater/Lesser Occipital Nerve Blocks Clinical Trial Eligibility Overview. Trial Name: NCT05732532 — Phase 4
Headache Research Study Groups: Anesthetic without steroid group, Anesthetic with dexamethasone group
Headache Clinical Trial 2023: Greater/Lesser Occipital Nerve Blocks Highlights & Side Effects. Trial Name: NCT05732532 — Phase 4
Greater/Lesser Occipital Nerve Blocks 2023 Treatment Timeline for Medical Study. Trial Name: NCT05732532 — Phase 4
~42 spots leftby Dec 2025